Karyn Kaplan Thai AIDS Treatment Action Group (TTAG) www.ttag.info.

Slides:



Advertisements
Similar presentations
Hepatitis B & Hepatitis C in HIV
Advertisements

European Guidelines for the HIV Treatment Esteban Martínez Infectious Diseases Unit Hospital Clínic University of Barcelona Barcelona SPAIN.
Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
Specific issues and guidelines for HCV treatment in IDUs Bern d Schulte Centre for Interdisciplinary Addiction Research (CIAR), University Hamburg.
Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014
HIV and Hepatitis B or C co-infection Preliminary results of survey.
Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland.
Annabel Baddeley Global TB Programme WHO, Geneva
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Edo Agustian Indonesian Drug Users Network Experiencing HCV Infection – the treatment, the reality and the possibilities for Cure.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
Management of HCV in Co-Infected Patients Marie-Louise Vachon, MD, MSc Division of Infectious Diseases Centre Hospitalier Universitaire de Québec.
Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.
MDL UMC utrecht Health Strategy on HCV in The Netherlands van Hattum VHPB meeting May 2002.
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
4th UK-CAAB - Hepatitis coinfection HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy’s & St Thomas’ Hospital London.
Inputs to a case-based HIV surveillance system. Objectives  Review HIV case definitions  Understand clinical and immunologic staging  Identify the.
Greenview Hepatitis C Fund Deborah Green Home: Cell: /31/2008.
Hepatitis C Virus Infection Hepatitis C Virus Infection Burden of Disease in United States New infections (cases)/year , ,000 Persons.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
Renal Transplantation for HIV/HCV Co-infected Patients Solid Organ Transplantation and People With HIV: Ethics and Policy Conference David Oldach & Robert.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
1 First Clinic Visit for Patients with HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Hepatitis C: The Next Tsunami Danny Jenkins Cri-Help Common Ground – The Westside HIV Community Center We Write the Grants
Update on the HCV Antiviral Pipeline Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease.
National Audit Group National Audit of Sexual Healthcare for People with HIV Infection National Audit Group British Association for Sexual Health & HIV.
Maxime Journiac : ANRS-ISVHLD Paris July Obstacles to Hep C TREATMENT: The patient’s point of view.
Sara Stevenson Hepatitis B Nurse Specialist St James’s Hospital, Leeds.
HEPATITIS MOBILE TEAM News Tools of screening viral hepatitis in real life: the french model of care André-Jean REMY (1,2), Hugues WENGER (1), Hakim BOUCKHIRA.
Research and Advocacy to Ensure Health and HIV Services for HIV-positive Women in Chiang Mai Women's Prison Wednesday, July 21 Paisan Suwannawong, Thai.
Health systems barriers to adherence in antiretroviral treatment programmes in rural South Africa Dr Brian van Wyk School of Public Health University of.
SPHUNGA HEALTHLINK “WORKER INTERVENTION PROGRAMME” 1.
Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS
ADAP and Hepatitis B Coverage  In June 2012, 29 ADAPs covered at least one of the medications for HBV on their formularies.  ADAPs filled 325 hepatitis.
Colleen Daniels Stop TB Department World Health Organisation TB, HIV and Drug Use The overview.
SPECIAL CONSIDERATIONS August
Integration of collaborative TB/HIV activities with harm reduction services Maryna Zelenskaya Ph D State service on HIV/AIDS and other socially diseases.
Hepatitis C Needs Assessment: Contributions from the National HCV Diagnosis and Local Clinical Databases.
Uniting Forces for Access to Hepatitis C Treatment Global Epidemiology Global Epidemiology & Treatment Access Issues & Treatment Access Issues Tracy Swan.
Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.
CASE 1 54 yo man HIV Generalized Anxiety/OCD VL 15,185 CD4 ranges from Baseline Genotype clear.
Luís Mendão European AIDS Treatment Group, GAT/H-CAB ELPA Symposium Compassionate use programs for hepatitis C patients with advanced disease Saturday,
Organizing Drug Users for Public Health Policy Changes 17 th International Conference on the Reduction of Drug Related Harm Jason Farrell, Executive Director.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Services and C Leon Wylie Lead Officer Hepatitis Scotland.
Edo Agustian Indonesian Drug Users Network Meaningful Involvement of PWID in Hep C advocacy in Indonesia.
More Than Just a Cut: Voluntary Medical Male Circumcision Programs Can Address Low HIV Testing and Counseling Usage and ART Enrollment among Young Men:
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
HIV Epidemic in Malaysia. HIV BY AGE GROUPS - MALAYSIA.
Role of Ministry of Health and Medical Education in management and control of Hepatitis C 2016/07/13.
Implementing a priority national health care project in Russian Federation (HIV prevention and treatment) Т.Т.Smolskaya October 2006 Expert Group.
Hepatitis C Consultation Services (844) | 9AM-5PM ET, M-F nccc.ucsf.edu The Clinician Consultation Center (CCC) provides up-to-date expert clinical.
Abstract MOAB0301 Hepatitis C Care Cascade for People Living With HIV in the Country of Georgia Nikoloz Chkhartishvili1, A. Abutidze1, N. Bolokadze1, O.
Thai AIDS Treatment Action Group (TTAG)
2017 Key Considerations for adolescents and children & Key populations
Scaling up Hepatitis C diagnosis and treatment in Punjab
Current harm reduction program at outreach
Phase 3 Treatment-Naïve and Treatment-Experienced
A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova
Integrating Hepatitis C Treatment in Primary Care
Expanding the Universe of Viral Hepatitis Treaters
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
Care of the Treatment-naive Patient With HCV/HIV Coinfection
Blood borne viral hepatitis action in Wales
From TB control to integrated respiratory disease control
Professor Jack Lambert
Lesson 3: The HCV Care Continuum
Presentation transcript:

Karyn Kaplan Thai AIDS Treatment Action Group (TTAG)

 Thailand: Population: 62 million  Est. HCV prevalence reports range from.7% - 5% in voluntary blood donors (active/inactive unspecified)  IDU population: 160,000  Est. HCV prevalence 92.5%  IDU HIV/HCV co-infection 88-96%  JAIDS: “…almost universal prevalence of HCV in HIV-infected IDU…”  “…a diagnosis of HIV in IDU should indicate probable HIV/HCV co-infection”

 Antibody test ( THB*)  Screened if suspected IDU  If HIV+ every mos. basic liver enzyme testing performed  Many Bangkok IDU get their health care in context of clinical trials  Genotyping (2,500 – 7,000 THB)  Diagnostic tests can be ordered by physician and paid for under universal health care, rarely practised in reality and genotyping available only in few major city hospitals a. IDU have little access to health care b. Negative attitude toward providers toward IDU adherence capaciy further inhibits access to diagnostics and treatment, including ART c. Lack of access to treatment precludes urgency of diagnostics (prohibitive cost most frequently-stated problem) HCV Viral Load (2,500 THB) “So many (hepatitis) tests” – confirmatory, ultrasound (800 THB), monitoring side effects (100 THB) “HIV gets priority, ie, cd4 will be performed over hepatitis diagnostics with limited hospital budgets” *1 USD = 35 THB

 International guidelines  Leading hepatologists at major public hospital still only treating 3-5 cases/year  Both Roche and Schering-Plough tx available, ribavirin cheap or free; PEG-IFN 7,000/dose x 24 or 48 weeks or $10-15,000 USD/person  “How can we get away from Roche and get IFN from China?”  IFN v. PEG-IFN efficacy study completed, equally effective SVR

 Side effects include: astemia, anemia, leucopenia, nausea, anorexia, headache, insomnia, fever  Provision of anti-depressants or NSIADS  Dose reductions or discontinuation  HIV exclusion criteria; also, alcohol/drug use  Mixed willingness to treat OST clients

 WHO IS GOING TO PAY?  Patient education – integrate hepatitis issues into HIV care and drug treatment? What to ask your doctor. Earlier access to HIV tx  Provider education – training across disciplines (HIV, hepatology, drug treatment) and improved treatment guidelines; med school curriculum  Improve referral system  Improve health care system (health care worker shortage, rotation of doctors, lack of support for nurses)

 Prison health care capitation 100 THB/person  Universal health care – not cover HAV, HBV vax or screening  Lack of harm reduction services and less IDU in care  Organization of IDU/PLWHA/NGOs/providers/GPO/NHSO/MSF and need for global campaign